← feed

Is NCT02122913 results overdue?

Yes — results are overdue. Primary completion was 2017-02-01; the FDAAA-801 reporting deadline (2018-02-01) passed 3062 days ago and no results are posted on ClinicalTrials.gov.

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

NCT IDNCT02122913 ↗
SponsorBayer (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2017-02-01 (ACTUAL)
Reporting deadline2018-02-01 (completion + 365d)
Days overdue3062
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 76015f9998757a6f… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02122913. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →